There is no doubt that the advanced therapies sector is growing at an exponential rate. According to a recently published 2021 Report by ARM (Alliance for Regenerative Medicine), the sector has raised $14.1B in financing in the first half of 2021 which is already 71% of what was raised in all of 2020. In addition, there are over 2,600 advance therapy clinical trials being conducted with 264 of those trails being Phase 3 trials and another 1,500 being Phase 2 trials.
With a maturing pipeline, more and more products are approaching the point of development where pricing decisions and evidence will used to support payer and HTA engagement. Our panel of industry experts will discuss some of these considerations when preparing for the launch of an advanced therapy.
This panel discussion co-hosted by Endpoints Webinars and Precision Value & Health will be moderated by Greg Gregory (SVP & Managing Director at PRECISIONadvisors), and feature insights from Phil Cyr (SVP, Customer Solutions at Precision Value & Health), Sarah Pitluck (VP & Head, Global Pricing & Reimbursement Strategy at Spark Therapeutics), Katherine Reedy (SVP, Commercial at Castle Creek Bio), and Maria Törnsén (CCO at Passage Bio).
In this webinar you will learn:
- Important evidence needed to support pricing decisions
- How evidence differs between cell and gene therapies and by market assessment archetype.
- How organizations are thinking about advocacy and integrating the voice of the patient to guide evidence development and payer engagement.
- Insights into the evolution of price, evidence generation, reimbursement decisions and contracting strategies as the cell and gene therapy industry continues to grow.